MARKET

EYEN

EYEN

EYENOVIA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.660
-0.160
-5.67%
Closed 16:00 07/10 EDT
OPEN
2.750
PREV CLOSE
2.820
HIGH
2.750
LOW
2.622
VOLUME
61.97K
TURNOVER
--
52 WEEK HIGH
5.06
52 WEEK LOW
1.110
MARKET CAP
52.60M
P/E (TTM)
-1.9707
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EYEN stock price target is 11.50 with a high estimate of 19.00 and a low estimate of 6.00.

EPS

EYEN News

More
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
GlobeNewswire · 06/30 21:05
Eyenovia Reports Resumed Recruitment Of Phase 3 CHAPERONE Study For Progressive Myopia
Benzinga · 06/30 20:06
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020  and Change to a Virtual Meeting Format
GlobeNewswire · 06/11 21:10
Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
GlobeNewswire · 06/05 21:10
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/14 04:38
Eyenovia EPS misses by $0.01
Eyenovia (NASDAQ:EYEN): Q1 GAAP EPS of -$0.31 misses by $0.01. Cash of $13.66M (-3.5% Q/Q) Press Release
seekingalpha · 05/14 01:09
Eyenovia Q1 EPS $(0.310) Misses $(0.300) Estimate
Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.310) per share which missed the analyst consensus estimate of $(0.300) by 3.33 percent. This is a 38 percent increase over losses of $(0.500) per share from the
Benzinga · 05/13 20:08
Eyenovia Reports First Quarter 2020 Financial Results
NEW YORK, May 13, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
GlobeNewswire · 05/13 20:05

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About EYEN

Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing the patented piezo-print delivery technology. Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.
More

Webull offers kinds of Eyenovia Inc stock information, including NASDAQ:EYEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEN stock methods without spending real money on the virtual paper trading platform.